Plum Alley
VC Fund
New York, United States
Plum Alley is a venture firm investing in early stage, high growth technology and healthcare companies with at least one woman founder from the STEM fields. Plum Alley invests in advanced technologies and medical breakthroughs, disrupting huge markets and driving exponential value for people, the planet, markets, and the economy. The firm investsboth via the Plum Alley Venture Fund I LP as well as through Plum Alley Syndicates.As of April 30th, 2021, Plum Alley has invested over $35M across 24 companies.
- Total investments:
- 43
- Last investment:
- Lead investor:
- 0%
- Fund size:
- $1.8M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Plum Alley invests in
SoftwareHealth CareBiotechnologyArtificial IntelligenceEducation
Stages Plum Alley invests in
Series ASeries BFunding RoundSeedConvertible Note
Countries Plum Alley invests in
United StatesSweden
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Software 8 (19%)
- Health Care 7 (16%)
- Biotechnology 7 (16%)
- Artificial Intelligence 6 (14%)
- Education 3 (7%)
Stage
- Series A 17 (40%)
- Series B 10 (23%)
- Funding Round 5 (12%)
- Seed 4 (9%)
- Convertible Note 2 (5%)
Country
- United States 26 (60%)
- Sweden 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alicia Zheng
Associate , Plum Alley Ventures Company
|
Associate , Plum Alley Ventures Company | Total investments: 0 | Find email | |
Avantika Daing
Managing Partner, Plum Alley GP, Plum Alley Venture Fund 1 Founding Partner, PAVC
|
Managing Partner, Plum Alley GP, Plum Alley Venture Fund 1 Founding Partner, PAVC | Total investments: 2 | Find email | |
Benjamin Robbins
Senior Associate , Plum Alley Ventures Company
|
Senior Associate , Plum Alley Ventures Company | Total investments: 0 | Find email | |
Deborah Jackson
Founder, Plum Alley GP, Plum Alley Ventures Fund 1 , Founding Partner, PAVC
|
Founder, Plum Alley GP, Plum Alley Ventures Fund 1 , Founding Partner, PAVC | Total investments: 6 | Find email | |
|
Frances Walton
Executive Director
|
Executive Director | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Openwater
|
Openwater is developing a new generation of imaging technologies, with high resolution and low costs, enabling medical diagnoses and treatments, and a new era of fluid and affordable brain-to-computer communications | $54M / Venture - Series Unknown / Aug 22, 2024 | |
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $33M / Series B / May 29, 2024 | |
KETOS
|
KETOS provides hardware and software analytics solutions and real-time data for usage and flow across water systems and monitors water health parameters such as pH, dissolved solids, hardness, turbidity, and salinity. Meena Sankaran founded KETOS in 2015. It is headquartered in Milpitas, California. | $10M / Private Equity / May 21, 2024 | |
Juvena Therapeutics
|
Juvena Therapeutics is a venture-backed biopharma startup discovering novel protein-based therapeutics that promote tissue regeneration in the elderly and treat various age-related diseases. | $41M / Series A / Nov 08, 2022 | |
|
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $17M / Venture - Series Unknown / Sep 14, 2022 | |
Ashvattha Therapeutics
|
Ashvattha Therapeutics creates products that selectively target and treat human diseases. Ashvattha enables precision targeting for therapeutics eliminating off-target toxicity, systemic side effects, and immunogenicity seen in other platforms. Ashvattha has a pipeline of nine therapeutics in neurology, oncology, and ophthalmology. | $69M / Series B / Apr 27, 2022 | |
AiFi
|
AiFi's platform uses computer vision and real-time sensor intelligence to understand how people, objects, and environments interact within a physical space. By creating a continuously updated spatial understanding of the environment, AiFi allows physical locations to perceive, reason, and respond in real time.AiFi’s technology powersapplications such as frictionless checkout, real-time inventory awareness, and operational insights in retail environments. Beyond retail, the platform is designed to be extensible to any physical space where understanding movement, behavior, and context is critical. By bridging the gap between the digital and physical worlds, AiFi helps organizations operate more efficiently, improve user experiences, and unlock new ways of interacting with physical environments.At its core, AiFi transforms physical spaces into software-defined environments by making them measurable, adaptable, and intelligent. | $65M / Series B / Mar 11, 2022 | |
|
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $20M / Series A / Jan 10, 2022 | |
Helaina
|
Helaina builds better breast milk alternatives for the modern parent. It is dedicated to supporting parents with breastfeeding. It was founded in 2019 by Laura Katz and is headquartered in New York. | $20M / Series A / Nov 19, 2021 | |
Mammoth Biosciences
|
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordablepoint-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.Mammoth has also been working on developing a rapid COVID-19 test. | $150M / Series D / Sep 09, 2021 | |
| See all 43 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
EdTech Investors
18,221 investors
Education Investors
13,563 investors
SaaS VC Funds
61,208 investors
FAQ
What does Plum Alley invest in?
Plum Alley invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 43 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Plum Alley?
Public channels for Plum Alley include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Plum Alley?
The team at Plum Alley includes Alicia Zheng (Associate , Plum Alley Ventures Company), Avantika Daing (Managing Partner, Plum Alley GP, Plum Alley Venture Fund 1 Founding Partner, PAVC) and Benjamin Robbins (Senior Associate , Plum Alley Ventures Company), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
